D. Boral Capital Downgrades Tevogen Bio (NASDAQ:TVGN) to Hold

Tevogen Bio (NASDAQ:TVGN) was downgraded by stock analysts at D. Boral Capital from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Tevogen Bio in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $2.00.

Tevogen Bio Trading Down 26.2%

Shares of TVGN traded down $0.06 during mid-day trading on Wednesday, hitting $0.18. The company’s stock had a trading volume of 815,826 shares, compared to its average volume of 656,899. Tevogen Bio has a 1-year low of $0.18 and a 1-year high of $1.51. The firm has a 50-day simple moving average of $0.31 and a 200 day simple moving average of $0.53. The firm has a market capitalization of $36.32 million, a P/E ratio of -0.96 and a beta of -0.76.

Hedge Funds Weigh In On Tevogen Bio

Institutional investors and hedge funds have recently modified their holdings of the company. Bridgeway Capital Management LLC raised its holdings in Tevogen Bio by 66.7% in the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after acquiring an additional 33,000 shares during the last quarter. Deutsche Bank AG grew its position in shares of Tevogen Bio by 304.1% in the fourth quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after purchasing an additional 130,738 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in Tevogen Bio by 126.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock valued at $91,000 after purchasing an additional 152,572 shares during the last quarter.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.